Cellular and Molecular Mechanisms Underlie the Anti-Tumor Activities Exerted by Walterinnesia aegyptia Venom Combined with Silica Nanoparticles against Multiple Myeloma Cancer Cell Types

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Badr, Gamal ^a,b   Al Sadoon, Mohamed K ^c   Abdel Maksoud, Mostafa A ^c   Rabah, Danny M ^a   El Toni, Ahmed M ^d,e  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b Assiut University   (Egypt)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

^d KING SAUD UNIVERSITY   (Saudi Arabia)

^e CENTRAL METALLURGICAL RESEARCH AND DEVELOPMENT INSTITUTE CMRDI   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

BIM PROTEIN; CHEMOKINE RECEPTOR CXCR4; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; MITOGEN ACTIVATED PROTEIN KINASE; NANOPARTICLE; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE B; PROTEIN MCL 1; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SILICA NANOPARTICLE; SILICON DIOXIDE; SNAKE VENOM; STROMAL CELL DERIVED FACTOR 1; UNCLASSIFIED DRUG;

ACTIN FILAMENT; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CELL ACTIVITY; CELL ADHESION; CELL INVASION; CELL ISOLATION; CELL MIGRATION; CELL PROLIFERATION; CELL STRUCTURE; CELL SURFACE; CELL VIABILITY; CHEMOTAXIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ISOLATION; DRUG SYNTHESIS; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IC 50; INTRACELLULAR SIGNALING; MITOCHONDRIAL MEMBRANE POTENTIAL; MOLECULAR MECHANICS; MONOTHERAPY; MULTIPLE MYELOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; RECEPTOR BINDING; REGULATORY MECHANISM; SNAKE; WALTERINNESIA AEGYPTIA;

ACTIN CYTOSKELETON; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHEMOKINE CXCL12; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DRUG SCREENING ASSAYS, ANTITUMOR; ELAPID VENOMS; ELAPIDAE; ENZYME ACTIVATION; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; MEMBRANE POTENTIAL, MITOCHONDRIAL; MULTIPLE MYELOMA; NANOPARTICLES; POLYMERIZATION; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, CXCR4; SILICON DIOXIDE; TIME FACTORS;

WALTERINNESIA AEGYPTIA;

EID: 84870889501     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0051661     Document Type: Article

References (57)

1. Picot J, Cooper K, Bryant J, Clegg AJ, (2011) The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: a systematic review and economic evaluation. Health Technol Assess 15: 1-204.
2. Tuchman SA, Chao NJ, Gasparetto CG, (2012) Lenalidomide before and after Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma. Adv Hematol 2012: 712613.
3. Yoshie O, Imai T, Nomiyama H, (2001) Chemokines in immunity. Adv Immunol 78: 57-110.
4. Aggarwal R, Ghobrial IM, Roodman GD, (2006) Chemokines in multiple myeloma. Exp Hematol 34: 1289-1295.
5. Arya M, Patel HRH, Williamson M, (2003) Chemokines key players in cancer. Curr Med Res Opin 19: 557-564.
6. Moller C, Stromberg T, Juremalm M, Nilsson K, Nilsson G, (2003) Expression and function of chemokine receptors in human multiple myeloma. Leukemia 17: 203-210.
7. Fulton AM, (2009) The chemokine receptors CXCR4 and CXCR3 in cancer. Curr Oncol Rep 11: 125-131.
8. Alsayed Y, Ngo H, Runnels J, Leleu X, Singha UK, (2007) Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood 109: 2708-2717.
9. Rossi M, Di Martino MT, Morelli E, Leotta M, Rizzo A, et al. (2012) Molecular targets for the treatment of Multiple myeloma. Curr Cancer Drug Targets 12: 757-767.
10. Sun H, Zheng X, Wang Q, Yan J, Li D, et al. (2012) Concurrent blockade of NFκB and AKT pathways potentiates cisplatin's antitumor activity in vivo. Anticancer Drugs 23: 1039-1046.
11. Zhang CZ, Pan Y, Cao Y, Lai PB, Liu L, et al. (2012) Histone deacetylase inhibitors facilitate dihydroartemisinin-induced apoptosis in liver cancer in vitro and in vivo. PLoS One 7: e39870.
12. Badr G, Lefevre EA, Mohany M, (2011) Thymoquinone inhibits the CXCL12-induced chemotaxis of multiple myeloma cells and increases their susceptibility to Fas-mediated apoptosis. PLoS One 6: e23741.
13. Tiberio P, Cavadini E, Callari M, Daidone MG, Appierto V, (2012) AF1q: A Novel Mediator of Basal and 4-HPR-Induced Apoptosis in Ovarian Cancer Cells. PLoS One 7: e39968.
14. Bruckheimer EM, Kyprianou N, (2000) Apoptosis in prostate carcinogenesis. A growth regulator and a therapeutic target. Cell Tissue Res 301: 153-162.
15. Zhang A, Wu Y, Lai HWL, Yew DT, (2004) Apoptosis a brief review. Neuroembryology 3: 47-59.
16. Kouri FM, Jensen SA, Stegh AH, (2012) The role of Bcl-2 family proteins in therapy responses of malignant astrocytic gliomas: BCL-2L12 and beyond. Scientific World Journal 2012: 838916.
17. Oltvai ZN, Milliman CL, Korsmeyer SJ, (1993) Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74: 609-619.
18. Gao Q, Yang S, Kang MQ, (2012) Influence of survivin and Bcl-2 expression on the biological behavior of non-small cell lung cancer. Mol Med Report 5: 1409-1414.
19. Nishihori T, Alsina M, (2011) Advances in the autologous and allogeneic transplantation strategies for multiple myeloma. Cancer Control 18: 258-267.
20. Ishii Y, Hsiao HH, Sashida G, Ito Y, Miyazawa K, (2006) Derivative (1;7)(q10;p10) in multiple myeloma. A sign of therapy-related hidden myelodysplastic syndrome. Cancer Genet Cytogenet 167: 131-137.
21. Ladas EJ, Jacobson JS, Kennedy DD, Teel K, Fleischauer A, (2004) Antioxidants and cancer therapy: a systematic review. J Clin Oncol 22: 517-528.
22. Heiferman MJ, Salabat MR, Ujiki MB, Strouch MJ, Cheon EC, (2010) Sansalvamide induces pancreatic cancer growth arrest through changes in the cell cycle. Anticancer Res 30: 73-78.
23. Lam M, Carmichael AR, Griffiths HR, (2012) An Aqueous Extract of Fagonia cretica Induces DNA Damage, Cell Cycle Arrest and Apoptosis in Breast Cancer Cells via FOXO3a and p53 Expression. PLoS One 7: e40152.
24. Francis S, Markland A, (2001) Novel Snake venom disintegrin that inhibits human ovarian cancer dissemination and angiogenesis in an orthotopic nude mouse model. Haemostasis 31: 183-191.
25. Badr G, Al-Sadoon MK, El-Toni AM, Daghestani M, (2012) Walterinnesia aegyptia venom combined with silica nanoparticles enhances the functioning of normal lymphocytes through PI3K/AKT, NFκB and ERK signaling. Lipids Health Dis 2012: 11-27.
26. Al-Sadoon MK, Abdel-Maksoud MA, Rabah DM, Badr G, (2012) Induction of Apoptosis and Growth Arrest in Human Breast Carcinoma Cells by a Snake (Walterinnesia aegyptia) Venom Combined With Silica Nanoparticles: Crosstalk Between Bcl2 and Caspase 3. Cell Physiol Biochem 30: 653-665.
27. Son DJ, Park MH, Chae SJ, Moon SO, Lee JW, et al. (2007) Inhibitory effect of snake venom toxin from Vipera lebetina turanica on hormone-refractory human prostate cancer cell growth: induction of apoptosis through inactivation of nuclear factor kappa B. Mol Cancer Ther. 6: 675-83.
28. Barratt G, (2003) Colloidal drug carriers: achievements and perspectives. Cell Mol Life Sci 60: 21-37.
29. Badr G, Borhis G, Treton D, Moog C, Garraud O, et al. (2005) HIV type 1 glycoprotein 120 inhibits human B cell chemotaxis to CXC chemokine ligand (CXCL) 12, CC chemokine ligand (CCL) 20, and CCL21. J Immunol 175: 302-310.
30. Zhao W, Gu J, Zhang L, Chen H, Shi J, (2005) Fabrication of uniform magnetic nanocomposite spheres with a magnetic core/mesoporous silica shell structure. J Am Chem Soc 127: 8916-8917.
31. El-Toni AM, Khan A, Ibrahim MA, Labis JP, badr G, et al. (2012) Synthesis of double mesoporous core-shell silica spheres with tunable core porosity and their drug release and cancer cell apoptosis properties. J Colloid Interface Sci 378: 83-92.
32. Coleman EJ, Brooks KJ, Smallshaw JE, Vitetta ES, (2006) The Fc portion of UV3, an anti-CD54 monoclonal antibody, is critical for its antitumor activity in SCID mice with human multiple myeloma or lymphoma cell lines. J Immunother 29: 489-498.
33. Park MH, Jo MR, Won D, Song HS, Han SB, et al. (2012) Snake venom toxin from Vipera lebetina turanica induces apoptosis in colon cancer cells via upregulation of ROS- and JNK-mediated death receptor expression. BMC Cancer 12(1): 228.
34. Song JK, Jo MR, Park MH, Song HS, An BJ, et al. (2012) Cell growth inhibition and induction of apoptosis by snake venom toxin in ovarian cancer cell via inactivation of nuclear factor κB and signal transducer and activator of transcription 3. Arch Pharm Res 35: 867-876.
35. Jöhrer K, Hofbauer SW, Zelle-Rieser C, Greil R, Hartmann TN, (2012) Chemokine-dependent B cell-T cell interactions in chronic lymphocytic leukemia and multiple myeloma- targets for therapeutic intervention? Expert Opin Biol Ther 12: 425-441.
36. Azab AK, Runnels JM, Pitsillides C, Moreau AS, Azab F, et al. (2009) CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood 113: 4341-4351.
37. Zhang WB, Navenot JM, Haribabu B, Tamamura H, Hiramatu K, et al. (2002) A point mutation that confers constitutive activity to CXCR4 reveals that T140 is an inverse agonist and that AMD3100 and ALX40-4C are weak partial agonists. J Biol Chem 277: 24515-24521.
38. Pelus LM, Horowitz D, Cooper SC, King AG, (2002) Peripheral blood stem cell mobilization. A role for CXC chemokines. Crit Rev Oncol Hematol 43: 257-275.
39. Yang L, Froio RM, Sciuto TE, Dvorak AM, Alon R, et al. (2005) ICAM-1 regulates neutrophil adhesion and transcellular migration of TNF-alpha-activated vascular endothelium under flow. Blood 106: 584-592.
40. Oliva IB, Coelho RM, Barcellos GG, Saldanha-Gama R, Wermelinger LS, et al. (2007) Effect of RGD disintegrins on melanoma cell growth and metastasis: involvement of the actin cytoskeleton, FAK and c-Fos. Toxicon 50: 1053-1063.
41. Menu E, Asosingh K, Indraccolo S, De Raeve H, Van Riet I, (2006) The involvement of stromal derived factor 1alpha in homing and progression of multiple myeloma in the 5TMM model. Haematologica 91: 605-612.
42. Song JH, Kraft AS, (2012) Pim kinase inhibitors sensitize prostate cancer cells to apoptosis triggered by Bcl-2 family inhibitor ABT-737. Cancer Res 72: 294-303.
43. Park MH, Son DJ, Kwak DH, Song HS, Oh KW, et al. (2009) Snake venom toxin inhibits cell growth through induction of apoptosis in neuroblastoma cells. Arch Pharm Res 32: 1545-1554.
44. Thornberry NA, Lazebnik Y, (1998) Caspases: enemies within. Science 281: 1312-1316.
45. Salido M, Gonzalez JL, Vilches J, (2007) Loss of mitochondrial membrane potential is inhibited by bombesin in etoposide-induced apoptosis in PC-3 prostate carcinoma cells. Mol Cancer Ther 6: 1292-1299.
46. Kolluru LP, Rizvi SA, D'Souza M, D'Souza MJ (2012) Formulation development of albumin based theragnostic nanoparticles as a potential delivery system for tumor targeting. J Drug Target. 2012 Oct 5.
47. Hillaireau H, Couvreur P, (2009) Nanocarriers' entry into the cell: relevance to drug delivery. Cell Mol Life Sci 66: 2873-2896.
48. Wang J, Sui M, Fan W, (2010) Nanoparticles for tumor targeted therapies and their pharmacokinetics. Curr Drug Metab 11: 129-141.
49. Haque F, Shu D, Shu Y, Shlyakhtenko LS, Rychahou PG, et al. (2012) Ultrastable synergistic tetravalent RNA nanoparticles for targeting to cancers. Nano Today 7: 245-257.
50. Nam HY, Kwon SM, Chung H, Lee SY, Kwon SH, et al. (2009) Cellular uptake mechanism and intracellular fate of hydrophobically modified glycol chitosan nanoparticles. J Control Release 135: 259-267.
51. Koo H, Huh MS, Sun IC, Yuk SH, Choi K, et al. (2011) In vivo targeted delivery of nanoparticles for theranosis. Acc Chem Res 44: 1018-1028.
52. Lim SM, Kim TH, Jiang HH, Park CW, Lee S, et al. (2011) Improved biological half-life and anti-tumor activity of TNF-related apoptosis-inducing ligand (TRAIL) using PEG-exposed nanoparticles. Biomaterials 32: 3538-3546.
53. Koppolu B, Bhavsar Z, Wadajkar AS, Nattama S, Rahimi M, et al. (2012) Temperature-sensitive polymer-coated magnetic nanoparticles as a potential drug delivery system for targeted therapy of thyroid cancer. J Biomed Nanotechnol 8: 983-990.
54. Chen D, Tang Q, Li X, Zhou X, Zang J, et al. (2012) Biocompatibility of magnetic Fe(3)O(4) nanoparticles and their cytotoxic effect on MCF-7 cells. Int J Nanomedicine 7: 4973-4982.
55. Lühmann T, Rimann M, Bittermann AG, Hall H, (2008) Cellular uptake and intracellular pathways of PLL-g-PEG-DNA nanoparticles. Bioconjug Chem 19: 1907-1916.
56. Kozako T, Arima N, Yoshimitsu M, Honda SI, Soeda S, (2012) Liposomes and nanotechnology in drug development: focus on oncotargets. Int J Nanomedicine 7: 4943-4951.
57. Dos Santos T, Varela J, Lynch I, Salvati A, Dawson KA, (2011) Effects of transport inhibitors on the cellular uptake of carboxylated polystyrene nanoparticles in different cell lines. PLoS One 6: e24438.